DK1402075T3 - Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira - Google Patents

Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira

Info

Publication number
DK1402075T3
DK1402075T3 DK02739358.6T DK02739358T DK1402075T3 DK 1402075 T3 DK1402075 T3 DK 1402075T3 DK 02739358 T DK02739358 T DK 02739358T DK 1402075 T3 DK1402075 T3 DK 1402075T3
Authority
DK
Denmark
Prior art keywords
dengue viruses
attenuation
development
well
suitable mutations
Prior art date
Application number
DK02739358.6T
Other languages
English (en)
Inventor
Kathryn A Hanley
Stephen S Whitehead
Brian R Murphy
Joseph E Blaney Jr
Original Assignee
Us Gov Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Nat Inst Health filed Critical Us Gov Nat Inst Health
Application granted granted Critical
Publication of DK1402075T3 publication Critical patent/DK1402075T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK02739358.6T 2001-05-22 2002-05-22 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira DK1402075T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29304901P 2001-05-22 2001-05-22
PCT/US2002/016308 WO2002095075A1 (en) 2001-05-22 2002-05-22 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Publications (1)

Publication Number Publication Date
DK1402075T3 true DK1402075T3 (da) 2013-02-11

Family

ID=23127420

Family Applications (4)

Application Number Title Priority Date Filing Date
DK10181804.5T DK2292802T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira
DK10181786.4T DK2290109T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
DK02739358.6T DK1402075T3 (da) 2001-05-22 2002-05-22 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK10181776.5T DK2290108T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK10181804.5T DK2292802T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira
DK10181786.4T DK2290109T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10181776.5T DK2290108T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira

Country Status (8)

Country Link
US (10) US7226602B2 (da)
EP (5) EP2290109B1 (da)
AU (2) AU2002312011B2 (da)
BR (2) BRPI0209943B8 (da)
CA (5) CA3114957C (da)
DK (4) DK2292802T3 (da)
ES (4) ES2512715T3 (da)
WO (1) WO2002095075A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1554301T1 (sl) 2002-05-03 2011-01-31 Us Health VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
WO2006036233A1 (en) * 2004-06-14 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services West nile viruses with mutations in the 3’ terminal stem and loop secondary structure for use as live virus vaccines
EP1874346B1 (en) 2005-04-24 2014-06-25 Sanofi Pasteur Biologics, LLC Recombinant flavivirus vaccines
BRPI0613328A2 (pt) 2005-06-17 2011-01-04 Sanofi Pasteur cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna
ATE475706T1 (de) 2005-06-17 2010-08-15 Sanofi Pasteur Abgeschwächter dengue-serotyp-2-stamm
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
US20100316670A1 (en) * 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
US20110150914A1 (en) * 2008-06-09 2011-06-23 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US9265821B2 (en) 2009-02-17 2016-02-23 Glaxosmithkline Biologicals Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2430444B1 (en) * 2009-05-12 2014-01-08 Janssen R&D Ireland Method for identifying inhibitors against dengue virus
NZ618158A (en) 2009-06-01 2015-05-29 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CA2803014C (en) * 2009-06-17 2019-03-19 Stephen Woodford Determining haemodynamic performance
CA2770888C (en) 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CN105246506A (zh) 2013-06-21 2016-01-13 默沙东公司 登革病毒疫苗组合物及其使用方法
MX2016010360A (es) 2014-02-11 2016-11-30 Visterra Inc Moleculas de anticuerpo para el virus del dengue y uso de las mismas.
MX2017002949A (es) * 2014-09-05 2017-12-14 Univ New York State Res Found Arbovirus recodificado y vacunas.
SG11201704942QA (en) 2014-12-22 2017-07-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
WO2016115484A1 (en) * 2015-01-16 2016-07-21 Takeda Vaccines, Inc. Detection of particle-contained reverse transcriptase activity
EP3331559A4 (en) 2015-08-03 2019-03-06 The United States of America as represented by the Secretary of the Army, Walter Reed Army Institute Of Research (WRAIR) PROTEIN OF RECOMBINANT DENGUE ENHANCING IMMUNITY
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
EP3426292A1 (en) * 2016-03-11 2019-01-16 THE UNITED STATES OF AMERICA, represented by the S Live attenuated zika virus vaccine
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
BR112018071176A2 (pt) * 2016-04-14 2019-02-12 National University Of Singapore método rápido de produção de vacinas vivas atenuadas
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
GEP20237539B (en) 2017-12-07 2023-09-11 Merck Sharp & Dohme Llc Formulations of dengue virus vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6537557B1 (en) * 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン

Also Published As

Publication number Publication date
US20120114694A1 (en) 2012-05-10
BRPI0209943B1 (pt) 2020-10-13
US20200085939A1 (en) 2020-03-19
AU2008203275B2 (en) 2011-11-10
EP2292802A3 (en) 2011-03-23
US20070092534A1 (en) 2007-04-26
EP2292802B1 (en) 2015-01-14
EP2940154B1 (en) 2019-05-22
AU2002312011B2 (en) 2008-04-24
EP2940154A1 (en) 2015-11-04
BR122019026154B8 (pt) 2021-07-27
CA3060687A1 (en) 2002-11-28
DK2290109T3 (da) 2014-11-10
US11318196B2 (en) 2022-05-03
BR0209943A (pt) 2004-03-30
EP2290109B1 (en) 2014-08-13
CA2966716C (en) 2019-11-26
AU2008203275A1 (en) 2008-08-14
CA2755964A1 (en) 2002-11-28
CA3060687C (en) 2021-05-04
EP2290108B1 (en) 2014-07-23
US10500264B2 (en) 2019-12-10
BRPI0209943B8 (pt) 2021-05-25
DK2292802T3 (da) 2015-03-09
WO2002095075A1 (en) 2002-11-28
USRE45123E1 (en) 2014-09-09
US7226602B2 (en) 2007-06-05
ES2533085T3 (es) 2015-04-07
US20150064214A1 (en) 2015-03-05
CA3114957A1 (en) 2002-11-28
USRE45016E1 (en) 2014-07-15
EP1402075A1 (en) 2004-03-31
US8039003B2 (en) 2011-10-18
DK2290108T3 (da) 2014-10-20
US9707287B2 (en) 2017-07-18
ES2399420T3 (es) 2013-04-01
US8632782B2 (en) 2014-01-21
EP2292802A2 (en) 2011-03-09
US7560118B2 (en) 2009-07-14
US20090263424A1 (en) 2009-10-22
BR122019026154B1 (pt) 2020-11-24
USRE45053E1 (en) 2014-07-29
EP2290108A2 (en) 2011-03-02
US20050010043A1 (en) 2005-01-13
EP1402075B1 (en) 2012-11-14
EP2290109A3 (en) 2011-03-16
EP1402075A4 (en) 2005-05-11
CA2448329C (en) 2011-10-25
CA3114957C (en) 2022-02-08
EP2290109A2 (en) 2011-03-02
ES2512715T3 (es) 2014-10-24
CA2448329A1 (en) 2002-11-28
CA2755964C (en) 2017-06-27
CA2966716A1 (en) 2002-11-28
US20180008693A1 (en) 2018-01-11
EP2290108A3 (en) 2011-03-09
ES2523168T3 (es) 2014-11-21

Similar Documents

Publication Publication Date Title
DK1402075T3 (da) Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1451143T3 (da) Fremgangsmåder til fremstilling af O-desmethylvenlafaxin
DK1520175T3 (da) Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer
NO20023283D0 (no) Flammestopper
ECSP066436A (es) Compuestos heterociclicos fusionados
ATE288913T1 (de) N-heterocyclylsubstituierte thienyloxy-pyrimidine als herbizide
DE50204020D1 (de) Mikrotom
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1401863T3 (da) Kimære somatostatin-dopamin-analoge
NO20040775L (no) Oftalmisk sammensetning som innbefatter et askomycin
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
ATE356124T1 (de) Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one
DE50205159D1 (de) Zusammensetzungen enthaltend quaternäre Ammoniumverbindungen
DK1412486T3 (da) Fremgangsmåde til virusformering
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DE60201118D1 (de) Flüssigkeitserhitzer
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner
DK1660485T3 (da) Forbedret fremgangsmåde til fremstilling af alpha-polymorfisk eletriptanhydrobromid
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater